Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · STATUTE-COMPILATIONS · Patient Protection and Affordable Care Act · Sec. 10609

Sec. 10609. LABELING CHANGES

347 words·~2 min read·/statute-compilations/comps-9307/sec-10609

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 10609 LABELING CHANGES Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) is amended by adding at the end the following: > > #### “(10) > > > #####
(A)> > If the proposed labeling of a drug that is the subject of an application under this subsection differs from the listed drug due to a labeling revision described under clause (i), the drug that is the subject of such application shall, notwithstanding any other provision of this Act, be eligible for approval and shall not be considered misbranded under section 502 if— > > > ###### “(i) > > the application is otherwise eligible for approval under this subsection but for expiration of patent, an exclusivity period, or of a delay in approval described in paragraph (5)(B)(iii), and a revision to the labeling of the listed drug has been approved by the Secretary within 60 days of such expiration; > > > ###### “(ii) > > the labeling revision described under clause
(i)does not include a change to the ‘Warnings’ section of the labeling; > > > ###### “(iii) > > the sponsor of the application under this subsection agrees to submit revised labeling of the drug that is the subject of such application not later than 60 days after the notification of any changes to such labeling required by the Secretary; and > > > ###### “(iv) > > such application otherwise meets the applicable requirements for approval under this subsection. > > > ##### “(B) > > If, after a labeling revision described in subparagraph (A)(i), the Secretary determines that the continued presence in interstate commerce of the labeling of the listed drug (as in effect before the revision described in subparagraph (A)(i)) adversely impacts the safe use of the drug, no application under this subsection shall be eligible for approval with such labeling.” > . * * * * * * * ## Subtitle G Provisions Relating to Title VIII * * * * * * * ## Subtitle H Provisions Relating to Title IX
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Sec. 10609
LABELING CHANGES
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.